Incidence of AEs, SAEs, MAAEs, and AESI;Incidence of local and systemic solicited AEs;Number of participants with symptomatic laboratory confirmed COVID-19;Post-treatment GMFRs in SARS-CoV2 S and/or RBD antibodies;Post-treatment GMTs in SARS-CoV2 S and/or RBD antibodies;Proportion of participants with post-treatment seroresponse (> 4-fold rise in titers) to the S and/or RBD antigens of GRAd-COV2

Incidence of AEs, SAEs, MAAEs, and AESI;Incidence of local and systemic solicited AEs;Number of participants with symptomatic laboratory confirmed COVID-19;Post-treatment GMFRs in SARS-CoV2 S and/or RBD antibodies;Post-treatment GMTs in SARS-CoV2 S and/or RBD antibodies;Proportion of participants with post-treatment seroresponse (> 4-fold rise in titers) to the S and/or RBD antigens of GRAd-COV2